To read the full story, subscribe or sign in.

Iaso buys out Innovent’s rights to CAR T Fucaso

July 8, 2024

Nanjing, China-based Iaso Biotherapeutics Co. Ltd. has bought out global rights to human anti-B cell maturation antigen CAR T Fucaso (equecabtagene autoleucel) from partner Innovent Biologics Inc.

BioWorld Clinical Deals and M&A Cancer Asia-Pacific China

Today's news in brief

BioWorld

BioWorld briefs for Sept. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Sept. 22, 2025.

The ‘molecular revolution’ driving R&D of new cancer therapeutics

BioWorld Asia

“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at...

CHMP recommends EU approval of Bayer’s Lynkuet for hot flashes

BioWorld

Following the first approvals in the U.K., Canada, Australia and Switzerland, the EMA’s Committee for Medicinal Products for Human Use (CHMP) is now recommending...

Elderly woman holding illustration of brain with missing puzzle piece

Remynd’s REM-127 yields positive phase II data in Alzheimer’s

BioWorld

Remynd NV has turned in positive phase IIa data for a new target in Alzheimer’s disease, showing that restoring calcium homeostasis in neurons reduces levels of...